A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/557 (2006.01) A61K 31/5575 (2006.01)
Patent
CA 2294779
A new method and compositions for the treatment of glaucoma and ocular hypertension are described. The method is based on the usage of EP1 prostanoid receptor agonists which effectively reduce the intraocular pressure but have no, or reduced effect on iris pigmentation. The prostaglandin analogue which is an EP1 selective agonist is applied topically on the eye.
L'invention concerne un procédé nouveau et des compositions correspondantes pour le traitement du glaucome et de l'hypertension oculaire. Le procédé repose sur l'utilisation d'agonistes de récepteur de prostanoïde EP¿1?, qui diminuent de manière efficace la tension intraoculaire, mais avec des effets nuls ou réduits sur la pigmentation de l'iris. On applique localement sur l'oeil l'analogue de prostaglandine qui est un agoniste sélectif vis-à-vis de l'EP¿1?.
Lake Staffan
Resul Bahram
Stjernschantz Johan
Gowling Lafleur Henderson Llp
Pharmacia & Upjohn Ab
LandOfFree
Prostaglandin derivatives devoid of side-effects for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostaglandin derivatives devoid of side-effects for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostaglandin derivatives devoid of side-effects for the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1957126